Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTRISIN versus SULFISOXAZOLE DIOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTRISIN versus SULFISOXAZOLE DIOLAMINE.
AZO GANTRISIN vs SULFISOXAZOLE DIOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Sulfisoxazole diolamine is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
2-4 g orally initially, followed by 4-8 g/day in 4-6 divided doses for urinary tract infections; 6-8 g/day in 4-6 divided doses for nocardiosis.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on CrCl.
5-10 hours (prolonged in renal impairment; normal half-life in adults ~6 hours)
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Renal: 70-100% (primarily as unchanged drug and acetylated metabolite); Biliary/Fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic